Brockman, Asa A Khurana, Rohit Bartkowiak, Todd Thomas, Portia L Sivagnanam, Shamilene Betts, Courtney B Coussens, Lisa M Lovly, Christine M Irish, Jonathan M Ihrie, Rebecca A
...
Published in
Cytometry. Part B, Clinical cytometry
Cyclic immunohistochemistry (cycIHC) uses sequential rounds of colorimetric immunostaining and imaging for quantitative mapping of location and number of cells of interest. Additionally, cycIHC benefits from the speed and simplicity of brightfield microscopy, making the collection of entire tissue sections and slides possible at a trivial cost comp...
Panda, Devasis Pathak, Amardeep Tejwani, Narender Pandey, Pooja Mehta, Anurag
Published in
Cytometry. Part B, Clinical cytometry
Devitt, Katherine A Oldaker, Teri Shah, Kalpesh Illingworth, Andrea
Published in
Cytometry. Part B, Clinical cytometry
In the clinical laboratory, flow cytometry assays are critical to providing diagnostic and prognostic information to the treating clinicians. A validation or verification provides confidence that the assay will yield reliable results that can be trusted to make critical medical decisions. The following performance specifications should be included ...
Hsu, Fan-Chi Hudson, Chad Wilson, Elisabeth R Pardo, Laura M Singleton, Timothy P Xu, Dongbin Zehentner, Barbara K Hitzler, Johann Berman, Jason Wells, Denise A
...
Published in
Cytometry. Part B, Clinical cytometry
Detection of measurable residual disease detection (MRD) by flow cytometry after the first course of chemotherapy is a standard measure of early response in patients with acute myeloid leukemia (AML). Myeloid leukemia associated with Down Syndrome (ML-DS) is a distinct form of AML. Differences in steady-state and regenerating hematopoiesis between ...
Zhou, Ting Karrs, Jeremiah Ho, Truc Doverte, Alyssa Kochenderfer, James N Shah, Nirali N Yuan, Constance M Wang, Hao-Wei
Published in
Cytometry. Part B, Clinical cytometry
Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B-lymphoblastic leukemia/lymphoma (B-ALL). In the setting of targeted immunotherapy, B-ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity o...
Jurado, Rebeca Huguet, Maria Xicoy, Blanca Cabezon, Marta Jimenez-Ponce, Ari Quintela, David De La Fuente, Cristina Raya, Minerva Vinets, Esther Junca, Jordi
...
Published in
Cytometry. Part B, Clinical cytometry
The presence of >94% classical monocytes (MO1, CD14++/CD16-) in peripheral blood (PB) has an excellent performance for the diagnosis of chronic myelomonocytic leukemia (CMML). However, the monocyte gating strategy is not well defined. The objective of the study was to compare monocyte gating strategies and propose an optimal one. This is a prospect...
Gao, Qi Liu, Ying Aypar, Umut Baik, Jeeyeon Londono, Dory Sun, Xiaotian Zhang, Jingping Zhang, Yanming Roshal, Mikhail
Published in
Cytometry. Part B, Clinical cytometry
Measurement of minimal/measurable residual disease (MRD) in B-lymphoblastic leukemia/lymphoma (B-ALL) has become a routine clinical evaluation tool and remains the strongest predictor of treatment outcome. In recent years, new targeted anti-CD19 and anti-CD22 antibody-based and cellular therapies have revolutionized the treatment of the high-risk B...
Ramalingam, Thulasi Raman Uthayasuriyan, Ragavi Prabhakar, Vikram Vaidhyanathan, Lakshman
Published in
Cytometry. Part B, Clinical cytometry
McMillan, Annabel Tran, Thien-An Galas-Filipowicz, Daria Camilleri, Marquita Lecat, Catherine Ainley, Louise Guo, Yanping Yong, Kwee Sive, Jonathan
Published in
Cytometry. Part B, Clinical cytometry
Achieving minimal residual disease (MRD) negativity following treatment for multiple myeloma (MM) is associated with improved progression free and overall survival. In the UK, MRD assessments in MM are not incorporated into routine clinical use outside trials. Widely used in other haematological malignancies, there is a role for widening the availa...
Huang, Sara L Fennell, Thomas Chen, Xia Huang, James Z
Published in
Cytometry. Part B, Clinical cytometry
Surface immunoglobulin (sIg) light chains are not always detected on mature B cells. This may present as a challenge for clonality determination in clinical flow cytometry. To explore the mechanism and diagnostic significance of sIg negative mature B cells, we retrospectively studied 14 cases of sIg negative reactive B-cell lymphocytosis and 89 cas...
